NEW YORK – Fluidigm disclosed on Monday that it has finalized a contract with the National Institutes of Health related to the production of its microfluidics-based molecular test for SARS-CoV-2.
NEW YORK – Fluidigm disclosed on Monday that it has finalized a contract with the National Institutes of Health related to the production of its microfluidics-based molecular test for SARS-CoV-2.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.